Top Story Today
A CRISPR Cure Before Kindergarten: FDA Clears Gene Therapy for Toddlers With Sickle Cell
The FDA approved Casgevy, the CRISPR-based gene therapy from Vertex, for sickle cell patients as young as two years old. In trials, all eight evaluable children went a full year or more without a single severe pain crisis. The logic is compelling: intervene before the disease causes irreversible organ damage. But the treatment requires myeloablative chemotherapy (one child died from busulfan toxicity), and the $2.2 million price tag collides with the reality that sickle cell disproportionately affects Black children on Medicaid.
Why it matters: This marks the first gene therapy approved for toddlers with sickle cell disease, establishing a regulatory precedent for pediatric gene editing and forcing a national conversation about whether a cure that exists on paper can reach the kids who need it most.
Read more →Regulatory Shakeups
The FDA Just Built a Fast Lane for One-Patient Drugs
A new FDA framework lets gene therapies win approval based on biological plausibility rather than massive trials, paired with $160 million from ARPA-H funding seven research teams. For the 95% of rare diseases with zero approved treatments, this "build once, deploy many" approach could be transformative. The catch: legal scholars worry the lower evidence bar could creep into common diseases where traditional trials are perfectly feasible.
Read more →FDA Whiplash on Moderna's Flu Shot Spooks Industry
The FDA initially issued a refusal-to-file letter for Moderna's mRNA flu vaccine, citing trial design objections. The agency later reversed its decision and accepted the amended application, after which the advisory panel unanimously backed it. The whiplash spooked Wall Street and raised fundamental questions about regulatory predictability under the current FDA leadership vacuum.
Read more →Clinical Breakthroughs
Bladder Cancer's Decades-Old Chemo Monopoly Just Ended
The FDA approved Keytruda plus Padcev for muscle-invasive bladder cancer with no cisplatin requirement, filling a gap that left nearly half of patients without effective perioperative therapy. The headline stat: 57% of patients had zero detectable cancer at surgery, versus 9% with surgery alone. Analysts project the bladder cancer franchise could exceed $5 billion in peak revenue.
Read more →CAR-T Before Cancer: 20 for 20 in Pre-Malignant Myeloma
A Dana-Farber trial gave CAR-T therapy to 20 patients who didn't have cancer yet, just high-risk smoldering myeloma. All 20 achieved undetectable disease within two months, with zero serious cytokine release syndrome events. It's a tiny, single-center study without a control arm, but the concept of intercepting cancer before it arrives could reshape oncology if it scales.
Read more →Business and Markets
CRISPR's First Cure Has a Grocery Delivery Problem
More than two years after approval, only about 60 patients have received Casgevy globally. The bottleneck isn't the gene editing; it's collecting enough stem cells to start the process. Some patients need six collection cycles, and roughly 10% never produce enough cells to qualify. Revenue hit $116 million in 2025, but the quarterly pattern remains bumpy enough that analysts call it a "show-me story."
Read more →J&J Lost 43% of Stelara Revenue. Wall Street Shrugged.
Biosimilar competition slashed Stelara from an $11 billion peak to roughly $1.7 billion in Q2 revenue, with eight copycats offering discounts up to 85%. But J&J's stock held steady because Tremfya (up 64% year over year) and the broader oncology portfolio more than filled the gap. It's a masterclass in surviving a patent cliff, or at least the first year of one.
Read more →AstraZeneca's AI Collaboration Aims to Pick Better Cancer Patients
AstraZeneca and Tempus AI built a framework that retroactively identified which patients would actually respond in immuno-oncology trials, increasing probability of technical success by roughly 5% per study—not by changing the drug but by refining patient selection. The system uses multimodal foundation models. The real test: whether prospective trials designed around AI-selected biomarkers can replicate these results.
Read more →